Smartwatch-Guided DOAC Therapy for Atrial Fibrillation
(REACT-AF Trial)
Trial Summary
What is the purpose of this trial?
This trial tests whether taking blood-thinning medication continuously or only when a smart watch detects an irregular heartbeat is better for adults with a history of irregular heartbeats and moderate stroke risk.
Will I have to stop taking my current medications?
Participants must be willing to stop taking their current Direct Oral Anticoagulant (DOAC) medication for the study. If you are on other medications like aspirin or NSAIDs, you may need to stop them if they are not within current medical guidelines.
What data supports the effectiveness of the drug Apixaban for atrial fibrillation?
Is Apixaban (Eliquis) generally safe for humans?
What makes the AFSW Guided DOAC therapy unique for atrial fibrillation?
The AFSW Guided DOAC therapy is unique because it uses a smartwatch to guide the administration of direct-acting oral anticoagulants (DOACs) like Apixaban, which helps in preventing strokes in patients with atrial fibrillation. This approach may offer a more personalized and continuous monitoring method compared to traditional DOAC therapy, potentially improving adherence and outcomes.1391011
Eligibility Criteria
This trial is for adults aged 22-85 with a history of Atrial Fibrillation (AF) and low-to-moderate stroke risk, who can use a smartwatch and smartphone. They must be on DOAC therapy but willing to stop if needed, not at high risk for non-cardioembolic stroke, without severe heart conditions or other health issues that increase bleeding risks.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either AFSW-guided, time-delimited DOAC therapy or continuous DOAC therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AFSW Guided DOAC (Device)
- Continuous DOAC therapy (Anticoagulant)
AFSW Guided DOAC is already approved in European Union, United States for the following indications:
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
- Prevention of deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery
- Treatment of deep vein thrombosis and pulmonary embolism
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
- Prevention of deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery
- Treatment of deep vein thrombosis and pulmonary embolism